Protection of Omicron Sub-Lineage Infection Against Reinfection with Another Omicron Sub-Lineage: Systematic Review, Meta-Analysis, and Meta-Regression - Worldwide, 2022-2023.

Xu Guo, Zuyao Cheng, Junhong Li, Yudan Song, Hui Zheng, Yamin Wang, Chao Ma, Zijian Feng

Abstract read

In one paragraph

Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xu GuoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Zuyao ChengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Junhong LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Yudan SongNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Hui ZhengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Yamin WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Chao MaNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Zijian FengChinese Preventive Medicine Association, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: Both the decline in immunity over time and the evolution of the virus play a role in the level of protection offered by a prior infection. What is added by this report?: Point estimates indicated variations in protection levels based on the initial infecting variant and the reinfecting variant. There was a consistent correlation between real-world protection, antigenic distance, and humoral immunity levels. Specifically, shorter antigenic distances and higher humoral immunity levels corresponded to enhanced real-world protection. What are the implications for public health practice?: Our findings suggest that virological and immunological studies could help identify and assess the epidemic risk posed by new variants before they become dominant. Prompt incorporation of the latest variants into the antigen components of the coronavirus disease 2019 (COVID-19) vaccines can significantly contribute to effective epidemic prevention and control measures.

Indexed as

Meta-analysisOmicronReinfectionSARS-CoV-2

Identifiers

PMID38966308

DOI10.46234/ccdcw2024.103

PMCPMC11219298

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-SA

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.